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accepted Septembetrial ﬁbrillation is the most common arrhythmia and is associated with signiﬁcant morbidity and mortality. The
autonomic nervous system contributes to the creation of atrial ﬁbrillation substrates. Atrial electrophysiology is
inﬂuenced differently by sympathetic and parasympathetic activation. Several strategies are available to modulate
the complex interaction between the autonomic nervous system and the heart. However, different approaches
target the problem differently making the prediction of arrhythmogenic and/or antiarrhythmic effects difﬁcult. We
discuss the role of the autonomic nervous system on the development of a substrate for atrial ﬁbrillation and explore
the potential antiarrhythmic and/or arrhythmogenic effect of modulation of the autonomic nervous system by renal
sympathetic denervation, ganglionated plexi ablation, ganglion stellatum ablation, high thoracic epidural
anesthesia, low-level vagal nerve stimulation, and baroreﬂex stimulation. (J Am Coll Cardiol 2014;63:215–24)
ª 2014 by the American College of Cardiology FoundationAtrial ﬁbrillation (AF) is the most common sustained
arrhythmia and is associated with signiﬁcant morbidity and
mortality (1). Besides several other mechanisms, such as
atrial stretch and atrial structural alterations (2–6), the
autonomic nervous system has been considered to contribute
to the creation of AF substrates (7). The autonomic nervous
system of the heart consists of extrinsic and intrinsic ganglia
(8). The parasympathetic components of the extrinsic cardiac
nervous system originate in the vagus nerve. The sympathetic
components originate primarily in the cervical spinal cord
and in the vagus nerve, which contains both sympathetic and
parasympathetic ﬁbers (9). Mechanical stress receptors,
baroreceptors, and chemoreceptors located in the heart and
great vessels modulate autonomic tone (8). Additionally,
groups of intrinsic ganglia form a complex neural network
composed of ganglionated plexi, which are located in the
atria in multiple locations and modulate the interactions
between the extrinsic and intrinsic nervous systems (10).
In this review, we discuss the role of the autonomic
nervous system on the development of substrates for AF and
explore the potential antiarrhythmic effect of modulation of
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r 10, 2013.Physiology of Afferent Signaling Regulating
Autonomic Innervation
The autonomic nervous system is regulated by several
mechanisms particularly by afferent signals arising from the
kidney, baroreceptors, carotid bodies (CB), and intracardiac
ganglionated plexi (GP).
Renal nerves. The renal nerves are major regulators of
kidney function, volume homeostasis, cardiac output, and
blood pressure control (11). Increased efferent nerve activity
mediates changes in renal function through innervations of all
essential renal structures including the renal vasculature, the
tubules, and the juxtaglomerular apparatus resulting in
volume retention, sodium reabsorption, reduction of blood
ﬂow, and renin-angiotensin-aldosterone system activation
(11). The kidney, however, also has an extensive network of
afferent unmyelinated ﬁbers that transmit important sensory
information to the central nervous system (11). Afferent ﬁbers
from the kidney have been shown to travel along with the
sympathetic nerves at the level of the kidney and then enter
the dorsal roots and project to neurons at both spinal and
supraspinal levels. Most of the brainstem regions involved in
cardiovascular control including the hypothalamus receive
inputs from the renal afferents, which carry information to the
central nervous system from renal chemo- and mechanore-
ceptors (11). Renal afferent nerve activity directly inﬂuences
sympathetic outﬂow to the kidneys and to other highly
innervated organs involved in cardiovascular control such as
the heart and peripheral blood vessels, predominantly by
modulating posterior hypothalamic activity (11).
Carotid baroreﬂex. The carotid baroreﬂex originates mainly
from a type of mechanoreceptor (baroreceptors) located in
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216the blood vessels detecting the
local blood pressure (12). Addi-
tional baroreﬂex input to the
brain comes from numerous other
mechanoreceptors, including those
found in the walls of the internal,
external, and common carotid
arteries, aorta, and kidney. The nu-
cleus tractus solitarius in the me-
dulla oblongata recognizes changes
in the ﬁring rate of action
potentials from the baroreceptors
(13). Carotid baroreﬂex buffers
acute changes in blood pressure
through modulation of both
parasympathetic and sympathetic
nervous systems. Stimulation of
baroreﬂex afferent nerves is sensedby the brain as blood pressure increases, resulting in
a compensating decrease in sympathetic activity and blood
pressure (13).
Carotid bodies. CB are chemoreceptors located on the
external carotid arteries close to the bifurcation with the
internal carotids. Afferent nerve ﬁbers join with the sinus
nerve before entering the glossopharyngeal nerve. Their
primary function is to regulate respiratory activity. This is an
important mechanism for maintaining arterial blood partial
pressure of oxygen and carbon dioxide, as well as hydrogen
ion concentration within appropriate physiological ranges. A
decrease in CB blood ﬂow results in cellular hypoxia,
hypercapnia, and decreased hydrogen ion concentration that
lead to an increase in receptor ﬁring (14). The threshold
partial pressure of oxygen for activation is about 80 mm Hg
(normal arterial partial pressure of oxygen is about 95 mmHg).
Any elevation of partial pressure of carbon dioxide, above
a normal value of 40 mm Hg, or a decrease in hydrogen ion
concentration below 7.4, causes receptor ﬁring. Stimulation
of the CB drives systemic sympathetic tone through direct
signaling to the nucleus tractus solitarius and rostral
ventrolateral medulla oblongata, resulting in an increase in
blood pressure and minute ventilation (12).
Ganglionated plexi. The heart’s intrinsic nervous system
consists of ganglia (ganglionated plexi), which contain local
circuit neurons of several types and chemo- and mechano-
sensory neurons, which are distributed throughout the heart
(5). GP are particularly well innervated with both adrenergic
and vagal nerve endings and are housed in so-called fat pads,
which are mainly located around the pulmonary vein ostia.
GP may modulate the interactions and balance between
extrinsic and intrinsic cardiac autonomic nervous systems
(10) and contain efferent cholinergic and adrenergic neurons
inﬂuencing the atrial myocardium. Different neuro-
modulations (e.g., by spinal cord stimulation) can stabilize
local circuit neurons of the intrinsic cardiac system attenu-
ating neuronally mediated atrial arrhythmias (15). Stochastic
interactions in intrinsic cardiac local circuit neurons controlregional cardiac function and excessive activation of these
neurons precedes and persists throughout episodes of atrial
ﬁbrillation in dog models (16). Additionally, high-frequency
electrical stimulation of autonomic ganglia in the pulmonary
vein area led to episodes of AF and atrial tachycardia that
could be inhibited by both sympathetic and vagal pharma-
cological blockade in dogs (17).Efferent Autonomic Innervation of the Atria
Atrial sympathetic innervation. Sympathetic nerves orig-
inate inside the vertebral column, toward the middle of the
spinal cord in the lateral horn, beginning at the thor-
acolumbar region of the spinal cord (levels T1 to L3,
speciﬁcally), and reach the stellate ganglion (or cervico-
thoracic ganglion or inferior cervical ganglion) located in
front of the neck of the ﬁrst rib and just below the subclavian
artery. At the synapses within the ganglia, preganglionic
neurons release acetylcholine, a neurotransmitter that acti-
vates nicotinic acetylcholine receptors on postganglionic
neurons. In response to sympathetic stimuli, postganglionic
neurons release norepinephrine, activating beta-receptors.
Beta-1-receptors compose 70% to 80% of all beta-
receptors in the normal atrium. The stimulatory beta-
adrenergic response is initiated via G protein subunit alpha
complexes (Ga), leading to the activation of adenyl cyclase
and subsequent protein kinase A–mediated phosphorylation
of L-type calcium channels, troponin I, and phospho-
lamban, resulting in increased calcium inﬂux. Sarcoplasmic
reticulum calcium channels (called ryanodine receptors),
release calcium in response to transmembrane calcium entry.
Ryanodine receptors are normally closed during diastole
but can open if they are functionally defective or if
the sarcoplasmic reticulum is calcium-overloaded (5,6,18).
Excess calcium is extruded to the extracellular space by the
Naþ/calcium exchanger. Due to the 3:1 stoichiometry
(3 Naþ ions are exchanged for 1 Ca2þ ion), the Naþ/
calcium exchanger is electrogenic and produces an inward
current that underlies delayed afterdepolarizations–related
ectopic ﬁring. Additionally, alpha-adrenergic stimulation
inhibits the cardiac transient outward potassium current
(Ito). On the other hand, beta-adrenergic receptor activation
increases L-type calcium current (ICaL), ultra-rapid delayed
rectiﬁed potassium current (IKur), slow delayed rectiﬁed
potassium current (IKs), and acetylcholine-dependent
potassium current (IKACh) (5). As a net result of sympathetic
stimulation, the plateau potential of the action potential is
increased (19,20), while the total action potential duration is
unaffected or even decreased (21).
Atrial parasympathetic innervation. The parasympathetic
nervous system originates from medial medullary sites
(nucleus ambiguous, nucleus tractus solitarius, and dorsal
motor nucleus) and is modulated by the hypothalamus.
Vagal efferents extend from the medulla to postganglionic
nerves that innervate the atria with a neurotransmission that
is modulated via nicotinic receptors.
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217On the cellular level, cholinergic muscarinergic receptors
(M2R) are the primary mediators of parasympathetic control
of heart function. M2R stimulation effects are opposite to
those of beta-adrenergic stimulation. M2R stimulation by
acetylcholine causes inhibition of adenyl cyclase and reduces
cyclic adenosine monophosphate via pertussis toxin-sensitive
Gai/o proteins, which leads to an attenuated ICaL and
hyperpolarization-activated current (If). M2R-stimulated Gi
also directly activates IKACh, leading to an effective refractory
period shortening in the atrium (2–6). The effect of vagal
stimulation on atrial refractoriness is heterogeneous because
of the heterogeneity in the distribution of parasympathetic
nerve endings and/or M2R (22). In contrast, the effect of
sympathetic stimulation on refractoriness is more homoge-
neous (22).
Autonomic Nervous System and Atrial Fibrillation
Exercise-induced AF may be sympathetically driven; in
contrast, the parasympathetic nervous system may contribute
to AF in young patients without structural heart disease
(23). Several observations suggest that the autonomic
nervous system plays an important role in the initiation and
the maintenance of AF. Studies in lone AF patients and in
animal models of intermittent rapid atrial pacing and
congestive heart failure have indicated that AF onset is
associated with simultaneous sympathovagal activation
rather than with an increase in vagal or sympathetic drive
alone (24–28). In animal models and humans, beta-
adrenergic agonists (isoproterenol and epinephrine) can
induce AF (29,30). Increased AF susceptibility in rats with
chronic endurance exercise is caused by vagal promotion and
occurs via augmented baroreﬂex responsiveness and
increased cardiomyocyte sensitivity to cholinergic stimula-
tion (31). Interestingly, it has been shown that post-
operative AF is more common in patients after lung
transplantation than in heart transplant recipients, who have
functional pulmonary vein isolation (PVI). Cardiac auto-
nomic denervation, which just occurs in heart transplant
patients, might explain reduced post-operative AF (32).
Additionally, in a large series of patients after orthotopic
heart transplantation, the majority of supraventricular
arrhythmias in stable patients can be attributed to macro-
re-entrant tachycardias (ﬂutter and scar re-entry). Catheter
ablation is effective in management of these arrhythmias. By
contrast, AF was never encountered in stable patients in this
series (33). Beta-receptor blockade by metoprolol was
effective in preventing recurrence of AF after successful
cardioversion (34,35).
Autonomic, Electrical, and
Structural Atrial Remodeling
Figure 1 summarizes the complex interaction between
electrophysiological changes induced by autonomic activa-
tion, autonomic remodeling, and other AF mechanisms: forexample, AF-induced electrical remodeling (electrical loop);
triggered activity (trigger loop); and structural changes, such
as those due to ﬁbrosis (structural loop).
Autonomic remodeling. Sympathetic hyperinnervation is
reported in patients with persistent AF (26). A heteroge-
neous increase in sympathetic innervation in the atria of
dogs subjected to rapid atrial pacing for prolonged periods
might lead to increased AF susceptibility (25). Ogawa et al.
(36) have shown increased sympathetic and vagal nerve
discharges before the onset of atrial arrhythmias in dogs with
pacing-induced congestive heart failure by direct nerve
recordings from the stellate ganglia and vagal nerves. Indeed,
the atrial tachyarrhythmias in dogs with pacing-induced
congestive heart failure were prevented by prophylactic
ablation of the stellate ganglion and the T2 to T4 thoracic
sympathetic ganglia (36). In the same model of pacing-
induced congestive heart failure, Ng et al. (24) recently
demonstrated increased sympathetic and parasympathetic
nerve growth in the left atrium; nerve growth was most
pronounced in the pulmonary veins and the posterior wall of
the left atrium.
Electrical remodeling. AF itself causes shortening of atrial
refractoriness, thereby contributing to the progression from
paroxysmal to more persistent forms of AF (AF begets AF),
early AF recurrence after cardioversion, and progressive drug
resistance of longer-lasting AF (2–6). Calcium enters atrial
cells with each action potential. During rapid atrial rates,
increased calcium loading initiates autoprotective mecha-
nisms that reduce calcium entry by calcium current inactiva-
tion andL-type calcium current down-regulation.This results
in decreased calcium loading and a shortening of the action
potential duration leading to a stabilization of re-entry cir-
cuits perpetuating AF (2–6) (electrical remodeling). Addi-
tionally, the high calcium load in the atrial cardiomyocytes
results in an increased spontaneous release of calcium from
the sarcoplasmic reticulum leading to atrial ectopies (trigger
loop), potentially initiating and perpetuating AF (2–6).
Interestingly, the cardiac autonomic system plays a role for
the acute atrial electrical remodeling during atrial tachypacing
as shortening in the atrial effective refractory period (AERP)
could be inhibited by GP ablation (37). Electrophysiological
changes induced by autonomic activation might also occur
during several pathophysiological conditions. Simulated
obstructive apneas in a pig model led to pronounced short-
ening of atrial refractoriness and increased AF inducibility,
which was mainly mediated by combined sympathovagal
activation (38,39). Additionally, forced inspiration-induced
acute atrial distension causes an arrhythmogenic atrial elec-
trical remodeling in a rat model for obstructive sleep apnea
(OSA), which was partly prevented by combined autonomic
blockade (40). In a dog model for central sleep apnea,
GP-ablation inhibited AF inducibility (41).
Structural remodeling. Structural remodeling is charac-
terized by increased atrial ﬁbrosis formation and car-
diomyocyte hypertrophy. Atrial tissue ﬁbrosis impairs
electrophysiological cell-to-cell coupling and conduction
Figure 1 Interaction of Autonomic Nervous System With Different Mechanisms of AF
Sympathetic activation increases calcium entry and the spontaneous release of calcium from the sarcoplasmic reticulum leading to atrial ectopies (trigger loop). Increased vagal
activation together with atrial ﬁbrillation (AF)–induced atrial electrical remodeling shortens action potential duration, facilitating re-entry and thereby promoting AF (electrical
loop). In the structural loop, atrial stretch during different conditions including congestive heart failure, hypertension, or obstructive sleep apnea (OSA) activates numerous
proﬁbrotic pathways resulting in atrial structural alterations and conduction disturbances, also facilitating re-entrant mechanisms. The circular positive-feedback enhancement
of these pathophysiological changes explains the general tendency of AF to become more stable with time. IKACh ¼ acetylcholine-dependent potassium currents. Figure by
Craig Skaggs.
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218(2–6). Long-term AF leads to myocyte hypertrophy and
increased endomysial ﬁbrosis associated with dissociated
conduction and electrical dissociation between the epicardial
layer and the endocardial bundle network that contributes to
the development of permanent forms of AF (42,43). Besides
AF itself, other conditions can cause structural alterations
in the atrium. Long-term hypertension leads to electro-
structural changes characterized by conduction abnormali-
ties, atrial inﬂammation and ﬁbrosis, and increased AF
inducibility (44). Congestive heart failure is associated with
the development of a structural remodeling characterized by
increased ﬁbrosis formation and alterations in gap junction
expression promoting heterogeneity of conduction and
pathways, facilitating micro-re-entry and macro-re-entry
(45). Long-term OSA is associated with signiﬁcant atrial
remodeling characterized by atrial enlargement, site-speciﬁc
and widespread conduction abnormalities, and longer sinus
node recovery in humans (46).
Taken together, atrial structural changes with autonomic
remodeling and acute electrophysiological changes inducedby autonomic activation may play a signiﬁcant role in the
creation of AF substrates.
Different Modalities to Inﬂuence the
Autonomic Nervous System
Modulation of the autonomic nervous system might be
a promising strategy to protect the myocardium from
proarrhythmic autonomic inﬂuences and the development of
electrical, autonomic, and structural atrial remodeling.
Possible targets are summarized in Figure 2.
Renal sympathetic denervation. Catheter-based renal
sympathetic denervation (RDN) signiﬁcantly lowers blood
pressure in patients with therapy-resistant hypertension
(47,48). Mechanistically, it has been observed that the
procedure resulted in a 47% reduction of renal norepi-
nephrine spillover measured with a radiochemical tracer
methodology using 3H-norepinephrine (47,48), as well as in
a 37% reduction in ﬁring of single sympathetic vasocon-
strictor ﬁbers, measured by single-muscle sympathetic nerve
Figure 2 Complex Neural Interaction Between Central Nervous System and Peripheral Organs
The efferent sympathetic ﬁbers (blue), afferent sympathetic ﬁbers (red), nervus vagus (yellow), and afferent parasympathetic ﬁbers (green) are shown. Different strategies to
modulate the autonomic nervous system are depicted ( ¼ stimulation; ¼ inhibition; AP ¼ action potential) (for a further explanation, see text). Figure by Craig Skaggs.
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219activity (49). These ﬁndings indicate a combined modula-
tion of efferent and afferent signaling at the kidney by RDN.
Effects of RDN on cardiac electrophysiology have already
been shown in animal models and humans. RDN results in
a reduction in heart rate and atrioventricular-conduction
velocity in humans (50). The effect of RDN on atrial elec-
trophysiology was investigated in chloralose/urethane anes-
thetized pigs. Neither AERP nor P-wave duration were
inﬂuenced by RDN excluding relevant changes in atrial
refractoriness and atrial conduction (51). Additionally,
sensitivity of GP (38) was not modulated by RDN. In a pig
model for obstructive sleep apnea, shortening in AERP (38),
acutely induced by applied negative thoracic pressure, was
mainly mediated by combined sympathovagal activation,
because it could be inﬂuenced by atropine, bilateral vagotomy,
or beta-receptor blockade (38,39). Compared with beta-
blocker treatment, RDN resulted in an even more
pronounced attenuation of AERP shortening during nega-
tive thoracic pressure, which might explain the superior
antiarrhythmic effect of RDN compared with beta-blocker
therapy in this animal model (39) (Fig. 3). Importantly,
clinically used antiarrhythmic drugs such as amiodarone or
sotalol displayed a considerably less-pronounced antiar-
rhythmic effect than did RDN in the same pig model for
OSA (52). Additionally, in an AF pig model with rapid
atrial pacing, RDN also showed antiarrhythmic effects.RDN reduced duration of pacing-induced AF. However,
AF-induced electrical remodeling was not attenuated (51).
Interestingly, in humans with AF as well as in anesthetized
pigs with AF induced by rapid atrial pacing, RDN reduces
heart rate during AF, which might reduce clinical symptoms
in patients with AF (51) (Fig. 4). In a small study in
humans, the atrial antiarrhythmic effects of circumferential
PVI combined with RDN were investigated (53) (Fig. 5).
Patients who received both procedures showed signiﬁcant
reductions in average systolic and diastolic blood pressure,
whereas those in the PVI-only group did not show any
signiﬁcant improvement in blood pressure (53). At the
1-year follow-up, 69% of patients who received both
procedures no longer had AF recurrences, compared with
29% of those in the PVI-only group (53). In a case report,
even RDN without PVI reduced blood pressure and atten-
uated paroxysmal AF episodes, which were symptomatic and
drug-resistant before RDN (54).
Potentially, RDN might display antiremodeling effects by
a variety of mechanisms. Hypertension, diabetes, and OSA
are associated with early and progressive changes in atrial
remodeling characterized by structural and electrophysio-
logical remodeling (55). Modulation of autonomic nervous
system by RDN has been shown to reduce blood pressure
(47,48), which was associated with reduction of left
ventricular mass (56) and improvement of arterial stiffness
Figure 3 Effect of RDN on AF Inducibility in a Pig Model for OSA
(A) Effect of renal sympathetic denervation (RDN) and atenolol followed by atropine on changes in atrial effective refractory period (AERP) induced by tracheal occlusion with
applied negative tracheal pressure (NTP) at -80 mbar (ordinate). (B) Representative atrial multiple action potential recordings during AERP measurements before and after RDN
or atenolol. (C) Percentage of tracheal occlusions with inducible atrial ﬁbrillation (AF) (ordinate) and effect of RDN and atenolol followed by atropine. OSA ¼ obstructive sleep
apnea. Modiﬁed with permission from Linz et al. (39).
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220and central hemodynamics (57) in patients with resistant
hypertension. That regression of electrocardiographic left
ventricular hypertrophy is associated with decreased inci-
dence of new-onset AF in patients with hypertension, which
has already been shown in a recent study (58). Additionally,
RDN has been shown to reduce sleep apnea severity (59)
and improve glucose metabolism and insulin sensitivity
(60) in patients with drug-resistant hypertension. Therefore,
RDN might reduce arrhythmogenic atrial autonomic
signaling and structural alterations. However, whether RDN
has an antiarrhythmic effect beyond normalization of blood
pressure remains to be determined. In ongoing studies on
RDN, the development of AF and of atrial structural
remodeling should be closely monitored.
Ganglionated plexi ablation. GP may modulate the
interactions between the systemic and intrinsic cardiac
autonomic nervous systems and contain efferent cholinergic
and adrenergic neurons. In large-animal studies, ablation of
the autonomic ganglia at the base of the pulmonary veins has
been shown to contribute to the effectiveness of PVI in
vagally induced AF and has also been shown to eliminate
rapid pulmonary vein ﬁring in response to GP high-
frequency stimulation (61). In a dog model for central
sleep apnea, GP ablation inhibited AF inducibility (41). GP
ablation, alone or with PVI, has been used in patients with
both paroxysmal and persistent AF with variable success,although success rates appear to be better in patients with
paroxysmal than persistent AF (62–64). The comparison of
GP ablation plus PVI versus PVI alone was investigated by
Katritsis et al. (64) in a randomized controlled trial. They
demonstrated that GP ablation signiﬁcantly improved
success rates after PVI compared to PVI alone. Although
autonomic denervation of the atria by GP ablation may
lower recurrence rates, particularly after PVI, recent studies
in dogs suggest that GP ablation after acute myocardial
infarction increases the risk of ventricular arrhythmias
compared with GP ablation of the normal heart (65). This
potential ventricular arrhythmogenic effect of GP ablation
under certain conditions needs to be evaluated in future
studies in more detail.
Ganglion stellatum ablation. The stellate ganglion (or
cervicothoracic ganglion) is a sympathetic ganglion formed
by the fusion of the inferior cervical ganglion and the ﬁrst
thoracic ganglion. Myocardial infarction results in persistent
increase in synaptic density of bilateral stellate ganglia and is
associated with increased stellate ganglionic nerve activity
indicating remodeling of the extracardiac autonomic nerve
activity and structure (66). Left cardiac sympathetic dener-
vation (surgical excision of stellate ganglion, together with
the second and third thoracic ganglia) reduces arrhythmia in
high-risk patients and dogs following myocardial infarction
(67,68), patients with long-QT syndrome (69), and patients
Figure 4
Effect of RDN on Atrial and Ventricular CL After
RDN or Sham Procedures
Rapid pacing induced AF without changing the atrial cycle length (CL) (A), but
signiﬁcantly prolonging the ventricular CL (B). This provides evidence for improved
rate control after induction of AF. Abbreviations as in Figures 1 and 3. Modiﬁed
with permission from Linz et al. (51).
Figure 5
Incidence of AF Recurrences in Patients With and
Without Renal Denervation
The group that underwent both pulmonary vein isolation (PVI) and renal denerva-
tion has a signiﬁcantly reduced atrial ﬁbrillation (AF) recurrence rate over time
compared with the control PVI-only group. AT ¼ atrial tachyarrhythmia. Modiﬁed
with permission from Pokushalov et al. (53).
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221with catecholaminergic polymorphic ventricular tachycardia
(69). Cryoablation of bilateral stellate and T2 to T4 thoracic
ganglia reduced paroxysmal AF induced by sympathetic
discharges in dogs with pacing-induced congestive heart
failure (70). Despite potential antiarrhythmic effects by left
cardiac sympathetic denervation, incidence of procedure-
associated complications such as Horner syndrome is <1%
and usually temporary if only the lower half of the stellate
ganglion is removed. Furthermore, sympathectomy has been
a treatment option for refractory angina.
High thoracic epidural anesthesia. High thoracic epidural
anesthesia reduced afferent and efferent sympathetic nerve
impulses to the heart. The overall reduction of sympathetic
tone and block of the cardiac ﬁbers by high thoracic epidural
anesthesia was observed in patients during cardiac surgery
and cardiopulmonary bypass (71,72). In patients with
refractory electrical storm, initiation of high thoracic
epidural anesthesia was associated with a subsequent
decrease in arrhythmia burden (73). In a dog model with
rapid atrial pacing, high thoracic epidural anesthesia pre-
vented sustained AF. This was associated with inhibition of
atrial autonomic nerve sprouting (74). A meta-analysis
showed that the use of high thoracic epidural anesthesia in
patients undergoing cardiac surgery reduces the risk of post-
operative supraventricular arrhythmias (75). However, at
least 2 trials were not able to show decreased incidence of
post-operative sustained AF despite a signiﬁcant reduction
in sympathetic activity (76,77). The deﬁnite effect of highthoracic epidural anesthesia on atrial electrophysiology and
arrhythmogenesis needs to be determined in future studies.
Low-level vagal nerve stimulation. Vagal stimulation
leads to M2R-mediated activation of atrial IKACh, leading to
a potent effective refractory period shortening that promotes
atrial arrhythmias (2–6). However, low-level vagal nerve
stimulation not resulting in reduction of heart rate and
atrioventricular conduction has been shown to result in
antiarrhythmic effects. The initial observation was that
intravenous phenylephrine increased blood pressure and
initiated a baroreﬂex independent of heart rate reduction.
This resulted in a suppression of pulmonary vein ﬁring in
patients (78) and resulted in a reduction of rapid atrial ﬁring
and AF (79). The antiarrhythmic effects have been shown to
involve nitric oxide signaling pathways (80) and vasostatin-1
signaling (81).
Baroreﬂex stimulation. Implantable devices for carotid
baroreceptor stimulation (BRS) produce an electric ﬁeld
stimulation of the carotid sinus wall (82) resulting in a sus-
tained reduction in peripheral sympathetic nervous system
activity and blood pressure (83,84). Signiﬁcant improve-
ments were observed in left atrial and left ventricular
structure and function after chronic BRS in patients with
resistant hypertension (85). However, BRS modulates
autonomic balance not just by sympathetic withdrawal, but
also by increased vagal activation, ﬁnally resulting in reduced
total body sympathetic drive (86,87). Reduced sympathetic
drive is generally considered to result in an atrial antiar-
rhythmic effect. In contrast, it could be speculated that
increased vagal tone, as associated with BRS, could poten-
tially shorten atrial refractoriness, thereby increasing the
vulnerable phase, resulting in stabilization of re-entry circuits
perpetuating AF (2–7). This is in contrast to the ventricle,
where the parasympathetic nervous system appears to
be protective against arrhythmias (88). In normotensive
Figure 6
Effect of Different Intensities of BRS on A-MAP,
HR, and BP
(A) Effect of different intensities of baroreceptor stimulation (BRS) (in percentage
of maximal BRS intensity) on atrial monophasic action potential duration ([A-MAP],
ms, basic cycle length ¼ 400 ms), heart rate ([HR], reduction in percent), and
blood pressure ([BP], reduction in percent). (B) Effect of BRS on A-MAP before and
after atropine. Modiﬁed with permission from Linz et al. (89).
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222anesthetized pigs, electrical BRS at an intensity used in
hypertensive patients resulted in a pronounced shortening in
atrial refractoriness that was associated with a pronounced
increase in AF inducibility (89). Interestingly, low-level BRS
not resulting in heart rate and blood pressure reduction just
resulted in moderate shortening in atrial refractoriness
(Fig. 6A) (89). BRS-induced AERP shortening was medi-
ated by an increase in vagal tone, as it was attenuated by
atropine (Fig. 6B). Whether chronic low-level BRS results
in antiarrhythmic effects, as shown for low-level vagal nerve
stimulation, needs to be investigated in future studies. In
ongoing studies on BRS, development of AF should be
closely monitored, especially in patients with structurally
remodeled atria.
Carotid body ablation. In rats with intermittent hypoxia,
surgical denervation of peripheral chemoreceptors prevented
the hypertensive response to hypoxic stimuli (90). Carotid
sinus denervation (denervation of both carotid body and
carotid sinus baroreceptors) prevented the development ofhypertension in young pre-hypertensive spontaneously
hypertensive rats and signiﬁcantly decreased arterial pressure
in adult hypertensive spontaneously hypertensive rats (91)
and hypertensive humans (92). Chemoreﬂex sensitivity is
enhanced in rabbits with pacing-induced congestive heart
failure (93), potentially increasing central sympathetic drive.
Up to now, there are no studies characterizing the effects
of CB denervation on atrial electrophysiology and the
occurrence of atrial arrhythmia. However, reduction in
systemic autonomic tone and blood pressure might reduce
arrhythmogenic atrial autonomic signaling and attenuate
atrial structural alterations.
Conclusions and Perspectives
Available data indicate that autonomic inﬂuences contribute
to the creation of AF. Therefore, modulation of the auto-
nomic nervous system is a promising strategy for antiar-
rhythmic treatment. However, different modalities approach
the problem differently, making the prediction of arrhyth-
mogenic and/or antiarrhythmic effects difﬁcult. Autonomic
denervation of the atria by GP ablation might lower recur-
rence rates, particularly after circumferential PVI in patients
with AF. High thoracic epidural anesthesia may play a role
in post-surgery AF management. The antiarrhythmic effects
of CB denervation and BRS are unknown and need to be
investigated in future studies. Modulation of the autonomic
system by RDN already showed promising results in animal
models and humans. Randomized trials are required to
investigate the deﬁnite effect of the different strategies on
atrial arrhythmogenesis.
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